About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 1136 record(s)
Req # A-2022-000740
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-108180-599.Organization: Health Canada
January 2023
Req # A-2022-000782
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-106461-602.Organization: Health Canada
January 2023
Req # A-2022-000819
Adverse Drug Reactions (ADRs) for SAPHRIS. Report numbers: E2B_01545648, E2B_00657295, E2B_01270976. ADR for SINEMET. Report number: 000373800. ADRs for SINGULAIR. Report numbers: 000598431, E2B_01077314, E2B_01306440, E2B_01376304, 000699646, E2B_01306467.Organization: Health Canada
January 2023
Req # A-2022-000821
Adverse Drug Reactions (ADRs). Report numbers: E2B_05472569, 000999107, 000997976, E2B_05467055, E2B_05463299, E2B_05448194, E2B_05503127, E2B_05452585, E2B_05453815, 000960447.Organization: Health Canada
January 2023
Req # A-2022-000904
Adverse Drug Reactions (ADRs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_05558965, E2B_05544981, E2B_05537712, E2B_05599047, E2B_05604335, E2B_05580572.Organization: Health Canada
January 2023
Req # A-2022-000925
Adverse Drug Reactions (ADRs) for Janumet. Report numbers: E2B_02916744, E2B_03434660, E2B_03473185, E2B_03813844, E2B_03858656, 000676798, 000916716, 000654307. ADRs for Januvia. Report numbers: E2B_03121380, E2B_03129110.Organization: Health Canada
January 2023
Req # A-2022-000941
Adverse Drug Reactions (ADRs) for SINGULAIR. Report numbers: E2B_01562019, E2B_01565633, E2B_01624629, E2B_01629372, E2B_01629377. ADRs for Zenhale. Report numbers: E2B_01648201, E2B_01651001, E2B_01413472, 000546550, E2B_00037157.Organization: Health Canada
January 2023
Req # A-2022-000944
Adverse Drug Reactions (ADRs). Report numbers: E2B_05020311, E2B_05020328, E2B_05020515, E2B_05020532, E2B_05033037, E2B_05020544, E2B_05033072, E2B_05033004, E2B_05033017, E2B_05032993.Organization: Health Canada
January 2023
Req # A-2022-000945
Adverse Drug Reactions (ADRs). Report numbers: E2B_05020606, E2B_05020616, E2B_05032964, E2B_05032933, E2B_05032880, E2B_05032845, E2B_05032806, E2B_05032800, E2B_05032776, E2B_05210116.Organization: Health Canada
January 2023
Req # A-2022-000946
Adverse Drug Reactions (ADRs). Report numbers: 000989134, E2B_05032774, E2B_05032735, E2B_05027671, E2B_05027668, E2B_05020637, E2B_05027331, E2B_05027460, E2B_05027521, E2B_05027592.Organization: Health Canada
January 2023